Articles related to CLINICAL STUDY

There aren’t as many headlines concerning cell phones and brain cancer today, despite it formerly being a mainstay of frightened online fodder. Have people lost interest and simply unwilling to give up their phones? Have the studies on the topic allayed their concerns? Or is it that people just don’t believe cell phones are one of the numerous cancer hazards? Experts weigh in.

In this phase 1-2 study, patients with triple-class-exposed relapsed or refractory multiple myeloma experienced a high proportion of profound and long-lasting responses to teclistamab. Infections and cytopenias were frequent, and most grade 1 or 2 toxicities were consistent with T-cell misdirection.

According to new information revealed in a study of the AHA’s COVID-19 Cardiovascular Disease Registry, new onset AFib occurs in 5% of patients hospitalized with COVID-19. Patients who developed new-onset AFib experienced longer hospital stays and approximately 45% died during their hospitalization. Atrial fibrillation can directly increase the risk of stroke and prolong hospitalization. It is also an indirect marker of the insult that the heart is experiencing when patients are infected with COVID-19.

Up to this point, individuals with non-alcoholic fatty liver disease (NAFLD) and a normal BMI have often been overlooked. It was assumed their normal BMI equated to a lower risk of more serious conditions than those who are overweight or obese. These findings indicate that lean patients with NAFLD are 50% more likely to have a CVA compared with overweight patients, and 10 to 30% more likely to experience CVD.

Seven-hundred patients with left ventricular ejection fraction (LVEF) of 35% or less, extensive coronary artery disease amenable to PCI, and demonstrable myocardial viability were randomly assigned to PCI plus optimal medical therapy vs. optimal medical therapy alone. At 6 months, the LVEF was similar between the two groups.

When compared with rivaroxaban in a propensity score–matched cohort of 19,894 patients, apixaban was associated with an approximately 50% lower rate of ischemic stroke or systemic embolism and bleeding compared to rivaroxaban.